FDA-Approved Cemiplimab-rwlc is Effective in the Treatment of Patients with Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) and Patients with Locally Advanced CSCC Who Are Not Candidates for Curative Surgery or Curative Radiation
FDA Approves Mepolizumab as Add-On Treatment for COPD
Balancing Fertility and Cancer Risk in BRCA+ Young Women
Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers